Aging is the most significant modifiable risk factor for most degenerative and chronic diseases in adult dogs. Targeting the ways dogs age and decline over time may be one of the most effective and practical ways for veterinarians to increase the healthy lifespan of their canine patients.
At Loyal, our approach is to help dogs live longer and stay healthier as they age by targeting the underlying processes that lead to age-associated disease and disability. Our drugs aim to extend lifespan and quality of life by reducing incidence or severity of age-related diseases.
LOY-002 is intended for dogs aged 10 or older and weighing at least 14 lb. It aims to extend healthy lifespan by targeting age-associated metabolic dysfunction.
As dogs age their metabolic health declines, leading to disease and reduced lifespan. Our aim with LOY-002 is to preserve metabolic health, which we believe will delay the onset of age-associated disease and help maintain better function and quality of life.
We’ve launched a double-blinded, placebo-controlled efficacy study recruiting 1,300 senior dogs in partnership with 70 veterinary clinics across the country. Learn more about the STAY study.
LOY-001 and LOY-003 are intended for large and giant dogs and target the over-expression of IGF-1, a hormone that we believe is associated with large dogs’ shorter lifespan relative to small dogs.
Large body size in dogs is correlated with shortened lifespan, so the larger a breed is, the shorter the average longevity of dogs in that breed. We believe that sustained higher levels of Growth Hormone and IGF-1 in larger dogs are partly responsible for shorter lifespan and the earlier development of age-associated disease and disability. Our aim for LOY-001 and LOY-003 is to address this overexpression in adult dogs with the aim of reducing age-associated diseases and extending healthy lifespan.
LOY-001 is a prescription long-acting injection for dogs 7 years or older and weighing at least 40 lb, while LOY-003 is a prescription daily pill for dogs 5 years or older and weighing at least 60 lb. Learn more about these products for large dogs.
- Full safety data
- Full manufacturing data
- Reasonable expectation of effectiveness
veterinary professionals
We've upgraded our CE platform with new courses, progress tracking, and certificates.
Koch, Z., Graves, J.L., Annan, S. et al. Multi-omic analysis of canine aging uncovers conserved aging pathways. GeroScience (2025). https://doi.org/10.1007/s11357-025-02029-2
McKenzie, B.A. (2025), Immunosenescence and Inflammaging in Dogs and Cats: A Narrative Review. J Vet Intern Med, 39: e70159. https://doi.org/10.1111/jvim.70159
McMahon, J.E., Graves, J.L., Tovar, A.P. et al. Translational immune and metabolic markers of aging in dogs. Sci Rep 15, 14460 (2025). https://doi.org/10.1038/s41598-025-99349-2
McKenzie, B., Peloquin, M., Graves, J.L. et al. Changes in insulin, adiponectin and lipid concentrations with age are associated with frailty and reduced quality of life in dogs. Sci Rep 15, 5380 (2025).
McKenzie B, Peloquin M, Tovar A, Graves JL, Ratcliff E, Tucker K, Vo K, Greenwood K, Halioua-Haubold CL, Juarez-Salinas D. Feeding dogs a high-fat diet induces metabolic changes similar to natural aging, including dyslipidemia, hyperinsulinemia, and peripheral insulin resistance. AVMA. 2024 Apr 15. (published online ahead of print 2024).
Chen FL, Ullal TV, Graves JL, Ratcliff ER, Naka A, McKenzie B, Carttar TA, Super KM, Austriaco J, Weber SY, Vaughn J, LaCroix-Fralish ML. Evaluating instruments for assessing healthspan: a multi-center cross-sectional study on health-related quality of life (HRQL) and frailty in the companion dog. GeroScience. 2023 Feb 13.
McKenzie BA, Chen FL, LaCroix-Fralish ML. The phenotype of aging in the dog: how aging impacts the health and well-being of dogs and their caregivers. AVMA. 2022 Jun 1;260(9):963-70.
McKenzie BA. Comparative veterinary geroscience: mechanism of molecular, cellular, and tissue aging in humans, laboratory animal models, and companion dogs and cats. AJVR. 2022 Jun 1;83(6).
McKenzie BA, Chen FL, Gruen ME, Olby NJ. Canine Geriatric Syndrome: A Framework for Advancing Research in Veterinary Geroscience. Front. Vet. Sci. 2022 April 21;9:853743.
Chen FL, Zimmermann M, Hekman JP, Lord KA, Logan B, Russenberger J, et al. Advancing Genetic Selection and Behavioral Genomics of Working Dogs Through Collaborative Science. Front. Vet. Sci. 2021 Sept 6;8:662429.
Booth 517
Booth 1832
The goal for all our programs is to develop FDA-approved drugs that extend healthy lifespan in dogs. By targeting specific pathways that lead to metabolic dysfunction, we believe we can delay age-associated disease and disability and give companion dogs substantially more time with good health, physical function, and quality of life. The STAY study and our other ambitious clinical trials will provide much more detail about the impacts of our drugs on health and lifespan.
In December 2025, LOY-002 completed its Target Animal Safety (TAS) package, the second of three major technical sections required for FDA conditional approval. The submission included a standard safety study as well as additional field safety data from 400 dogs in the STAY study. We’ll be able to share more data as we get closer to launch.
For LOY-001 and LOY-003, we will submit full safety data as part of our application for expanded conditional approval (XCA). We’ll be able to disclose this data as we get closer to launching each product.
Because our products are still in development, the drugs and their exact mechanisms of action necessarily remain confidential. We’ll release these details — along with safety and efficacy data — as we get closer to launching each product.
Our goal is to develop medications that preserve health and broadly delay or prevent age-associated disease, rather than focusing on treating specific diseases after they have already developed.
We expect to support the following populations with our drugs:
For LOY-002, dogs 10 years and older and between 14 and 179 pounds
For LOY-001 and LOY-003, dogs 7 years and older and at least 40 pounds
Clinical studies are designed to measure effectiveness among a target population, and for our lifespan extension drugs this means choosing a population that’s most likely to benefit over the duration of the study. If approved, our drugs will be labeled for use in the same populations studied in the clinical efficacy trials.
Our goal is to help as many dogs as possible, and we hope to pursue additional research to expand access to a broader population in the future.
We expect dogs with many pre-existing conditions will be able to take our drugs and benefit from them, but any specific guidelines will be based on the results of our clinical and safety studies.
LOY-002 aims to extend healthy lifespan by targeting age-associated metabolic dysfunction.
As dogs age their metabolic health declines, leading to disease and reduced lifespan. Our aim with LOY-002 is to preserve metabolic health, which we believe will delay the onset of age-associated disease and help maintain better function and quality of life.
LOY-001 and LOY-003 target the over-expression of IGF-1, a hormone that is associated with large dogs’ shorter lifespan relative to small dogs.
We believe that sustained higher levels of Growth Hormone and IGF-1 in large dogs are partly responsible for their shorter lifespan and the earlier development of age-associated disease and disability. Our goal for LOY-001 and LOY-003 is to address this overexpression in adult dogs with the aim of reducing age-associated diseases and extending healthy lifespan.
Our goal is to offer a range of options to suit the needs of veterinarians and dog owners.
A long-acting injection offers convenience and improved compliance, while a daily pill may be preferred by some owners.
We’ll be recruiting for our future studies soon. If you’re interested in being an investigator for our future clinical trials, send Dr. Mary Harrison a note at mary@loyal.com
At Loyal, we believe in transparency. We're currently in the FDA approval process, so we're limited on what we can share. As we (hopefully!) get closer to conditional approval, we can disclose more about our technical data and studies supporting safety and efficacy.
You can subscribe to our email list for updates and education on our products.